Determination of the effects of lactoferrin in a preclinical mouse model of experimental colitis.

Li Li,Fazheng Ren,Zhanyou Yun,Ying An,Caiyun Wang,Xudong Yan
DOI: https://doi.org/10.3892/mmr.2013.1632
IF: 3.423
2013-01-01
Molecular Medicine Reports
Abstract:The aim of this study was to determine the therapeutic efficacy of lactoferrin (Lf) on dextran sulphate sodium (DSS) -induced experimental colitis in BALB/c mice. Eighty BALB/c mice were randomly divided into 4 groups; the normal, model, apo-Lf and holo-Lf groups. Fecal character, fecal occult blood, hematochezia and disease activity index (DAI) were recorded daily. The length of the colon was measured and histological scores were evaluated 28 days post-treatment. Myeloperoxidase (MPO) activity was also determined and the expression of interleukin-1 beta (IL-1 beta) and tumor necrosis factor-alpha (TNF-alpha) were measured by quantitative (q)PCR. Lf relieved the inflammatory condition of DSS-induced experimental colitis in mice. The DAI and histological scores of Lf-treated mice were lower compared with those of mice in the control group. The length of the colon of Lf-treated mice was longer compared with that of mice in the control group. Treatment with Lf decreased MPO activity and the expression levels of IL-1 beta and TNF-alpha. In addition, Lf was found to promote beneficial effects in a mouse model of experimental colitis. Treatment with apo-Lf was superior to that of holo-Lf in the mouse model of DSS-induced experimental colitis. Supplemental therapy with apo-Lf may provide an important new tool in the clinical management of ulcerative colitis.
What problem does this paper attempt to address?